BLCONYSEOphthalmic GoodsFiscal year ends December 31
Bausch & Lomb Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$16.61+0.12 (+0.73%)
Close on Oct 19, 2026
- Market cap
- $5.93B
- P/E (TTM)
- –
- Dividend yield
- –
Bausch & Lomb Corp revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vision Care | $3.01B | $2.98B | $2.92B | $2.87B | $2.82B | $2.76B | $2.74B | $2.68B | $2.64B | $2.59B | $2.54B | $2.51B | 56.5% | +6.9% |
| Pharmaceuticals | $1.37B | $1.32B | $1.28B | $1.23B | $1.21B | $1.21B | $1.21B | $1.19B | $1.06B | $942.00M | $836.00M | $713.00M | 25.7% | +13.2% |
| Surgical | $948.00M | $908.00M | $894.00M | $876.00M | $867.00M | $860.00M | $843.00M | $816.00M | $795.00M | $781.00M | $767.00M | $751.00M | 17.8% | +9.3% |
| Operating income | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vision Care | $895.00M | $875.00M | $849.00M | $839.00M | $823.00M | $806.00M | $808.00M | $757.00M | $738.00M | $713.00M | $689.00M | $668.00M | +8.7% |
| Pharmaceuticals | $365.00M | $313.00M | $258.00M | $180.00M | $173.00M | $214.00M | $256.00M | $274.00M | $258.00M | $248.00M | $241.00M | $228.00M | +111.0% |
| Surgical | $49.00M | $34.00M | $18.00M | $19.00M | $24.00M | $26.00M | $44.00M | $49.00M | $45.00M | $50.00M | $50.00M | $36.00M | +104.2% |
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product sales | $5.30B | $5.19B | $5.08B | $4.96B | $4.87B | $4.81B | $4.77B | $4.67B | $4.48B | $4.30B | $4.13B | $3.95B | 99.6% | +8.8% |
| Devices | $2.01B | $1.95B | $1.92B | $1.88B | $1.85B | $1.82B | $1.80B | $1.75B | $1.71B | $1.67B | $1.65B | $1.63B | 37.7% | +8.4% |
| OTC | $1.89B | $1.87B | $1.83B | $1.81B | $1.77B | $1.74B | $1.72B | $1.69B | $1.68B | $1.65B | $1.61B | $1.58B | 35.4% | +6.3% |
| Pharmaceuticals | $1.17B | $1.13B | $1.08B | $1.03B | $997.00M | $982.00M | $969.00M | $964.00M | $830.00M | $719.00M | $618.00M | $484.00M | 21.9% | +16.9% |
| Branded and Other Generics | $247.00M | $237.00M | $243.00M | $240.00M | $251.00M | $269.00M | $281.00M | $263.00M | $265.00M | $257.00M | $252.00M | $265.00M | 4.6% | -1.6% |
| Other revenues | $21.00M | $22.00M | $21.00M | $19.00M | $19.00M | $16.00M | $17.00M | $17.00M | $16.00M | $17.00M | $15.00M | $15.00M | 0.4% | +10.5% |
| Other revenues | $21.00M | $22.00M | $21.00M | $19.00M | $19.00M | $16.00M | $17.00M | $17.00M | $16.00M | $17.00M | $15.00M | $15.00M | 0.4% | +10.5% |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Poland | – | – | – | – | – | – | $65.00M | $64.00M | $58.00M | $54.00M | $51.00M | $48.00M | – | – |
| Japan | – | – | – | – | – | – | $180.00M | $178.00M | $178.00M | $181.00M | $187.00M | $188.00M | – | – |
| France | – | – | – | – | – | – | $227.00M | $221.00M | $216.00M | $214.00M | $210.00M | $206.00M | – | – |
| Germany | – | – | – | – | – | – | $152.00M | $152.00M | $147.00M | $147.00M | $147.00M | $147.00M | – | – |
| Canada | – | – | – | – | – | – | $127.00M | $123.00M | $117.00M | $112.00M | $110.00M | $108.00M | – | – |
| U.S. and Puerto Rico | – | – | – | – | – | – | $2.41B | $2.35B | $2.21B | $2.07B | $1.93B | $1.80B | – | – |
| Italy | – | – | – | – | – | – | $91.00M | $89.00M | $86.00M | $85.00M | $82.00M | $76.00M | – | – |
| South Korea | – | – | – | – | – | – | $47.00M | $46.00M | $46.00M | $47.00M | $46.00M | $46.00M | – | – |
| United Kingdom | – | – | – | – | – | – | $132.00M | $129.00M | $127.00M | $123.00M | $121.00M | $116.00M | – | – |
| Spain | – | – | – | – | – | – | $92.00M | $89.00M | $87.00M | $86.00M | $85.00M | $83.00M | – | – |
| China | – | – | – | – | – | – | $358.00M | $356.00M | $351.00M | $347.00M | $344.00M | $342.00M | – | – |
| Russia | – | – | – | – | – | – | $120.00M | $118.00M | $113.00M | $110.00M | $106.00M | $118.00M | – | – |
| Mexico | – | – | – | – | – | – | $75.00M | $73.00M | $74.00M | $69.00M | $68.00M | $66.00M | – | – |
| Other | – | – | – | – | – | – | $712.00M | $697.00M | $684.00M | $672.00M | $655.00M | $700.00M | – | – |
From the segment and revenue-disaggregation notes of Bausch & Lomb's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.